Graphite Bio, Inc. (GRPH)

Graphite Bio, Inc. (GRPH) Healthcare & Pipeline Overview

Graphite Bio, Inc. is a clinical-stage biotechnology firm specializing in gene editing therapies for severe diseases like sickle cell disease, X-linked severe combined immunodeficiency syndrome, and Gaucher disease. Their focus on directly correcting genetic mutations distinguishes them within the competitive gene editing landscape, though they face significant clinical and regulatory hurdles.

What Is the Investment Thesis for GRPH?

Graphite Bio presents a high-risk, high-reward investment opportunity within the gene editing space. The company's focus on directly correcting genetic mutations offers the potential for curative therapies, particularly for sickle cell disease with GPH101. However, the company's negative profit margin of -336.5% highlights its reliance on future clinical and regulatory successes. Key value drivers include positive clinical trial data for GPH101, GPH201, and GPH301, as well as potential partnerships or acquisitions. The company's low Beta of 0.20 suggests lower volatility compared to the broader market. Upcoming clinical trial milestones and regulatory decisions represent significant catalysts. Conversely, potential risks include clinical trial failures, regulatory setbacks, and competition from other gene editing companies. Investors should closely monitor clinical trial outcomes and cash runway.

Based on FMP financials and quantitative analysis

GRPH Key Highlights

• Market capitalization of $185.19M reflects investor sentiment and growth expectations in the gene editing sector.
• Negative P/E ratio of -6.06 indicates the company is currently unprofitable, typical for clinical-stage biotech firms.
• Gross margin of 99.3% suggests strong potential profitability if products reach commercialization.
• Beta of 0.20 indicates lower volatility compared to the market, potentially appealing to risk-averse investors.
• No dividend yield reflects the company's focus on reinvesting earnings into research and development.

Who Are GRPH's Competitors?

GRPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GRPH's Key Strengths?

• Proprietary gene editing platform.
• Focus on curative therapies for genetic diseases.
• Pipeline of product candidates targeting unmet needs.
• Experienced management team.

What Are GRPH's Weaknesses?

• Clinical-stage company with no approved products.
• High cash burn rate.
• Reliance on clinical trial success.
• Limited commercialization experience.

What Could Drive GRPH Stock Higher?

• Clinical trial data releases for GPH101 in sickle cell disease.
• Regulatory updates regarding GPH101's path to approval.
• Progress in clinical trials for GPH201 in X-linked SCID.
• Advancement of GPH301 into clinical development for Gaucher disease.
• Potential partnerships and collaborations to expand pipeline.

What Are the Key Risks for GRPH?

• Negative return on equity (-46.8%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failures for GPH101, GPH201, or GPH301.
• Regulatory delays or rejection of product candidates.
• Competition from other gene editing companies.
• High cash burn rate and need for additional funding.
• Ethical and societal concerns surrounding gene editing.

What Are the Growth Opportunities for GRPH?

• Advancement of GPH101 for Sickle Cell Disease: GPH101 represents a significant growth opportunity for Graphite Bio. The sickle cell disease market is estimated to be substantial, with a significant unmet need for curative therapies. Positive clinical trial results and regulatory approval could drive significant revenue growth. The timeline for potential commercialization depends on clinical trial progress and regulatory review, with potential market entry within the next 3-5 years. Success hinges on demonstrating superior efficacy and safety compared to existing treatments and gene therapies.
• Development of GPH201 for X-linked Severe Combined Immunodeficiency (X-SCID): GPH201 targets a rare but severe genetic disorder, X-SCID. While the patient population is smaller than that for sickle cell disease, the potential for a curative therapy represents a significant opportunity. The market for X-SCID treatments is underserved, and successful development of GPH201 could establish Graphite Bio as a leader in this niche area. Clinical trials are ongoing, and potential regulatory approval could occur within the next 3-5 years.
• Expansion into Gaucher Disease with GPH301: GPH301 aims to address Gaucher disease, another genetic disorder with significant unmet needs. The Gaucher disease market is well-established, but existing treatments have limitations. GPH301 offers the potential for a more effective and convenient therapy. Clinical development is underway, and positive data could lead to regulatory approval and commercialization within the next 4-6 years. Competition in the Gaucher disease market includes enzyme replacement therapy and substrate reduction therapy.
• Strategic Partnerships and Collaborations: Graphite Bio can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its gene editing therapies. These partnerships could provide access to additional funding, expertise, and resources. Potential partners include companies with established presence in hematology, immunology, and genetic diseases. The timeline for securing partnerships depends on the progress of clinical trials and the attractiveness of Graphite Bio's pipeline.
• Expansion of Gene Editing Platform to New Therapeutic Areas: Graphite Bio's gene editing platform has the potential to be applied to a wide range of genetic diseases beyond sickle cell disease, X-SCID, and Gaucher disease. Expanding the platform to new therapeutic areas could create additional growth opportunities and diversify the company's pipeline. Potential target areas include other hematologic disorders, inherited metabolic diseases, and rare genetic conditions. The timeline for platform expansion depends on research and development efforts and the identification of suitable targets.

What Opportunities Does GRPH Have?

• Positive clinical trial results.
• Regulatory approval of GPH101 and other candidates.
• Strategic partnerships with larger pharmaceutical companies.
• Expansion of gene editing platform to new therapeutic areas.

What Threats Does GRPH Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from other gene editing companies.
• Ethical concerns surrounding gene editing.

What Are GRPH's Competitive Advantages?

• Proprietary gene editing technology.
• Focus on directly correcting genetic mutations.
• Pipeline of potential therapies for underserved genetic diseases.
• Intellectual property protection for its gene editing platform.

What Does GRPH Do?

Graphite Bio, Inc., founded in 2017 and headquartered in South San Francisco, California, is a clinical-stage gene editing company dedicated to developing transformative therapies for severe and life-threatening diseases. Originally named Integral Medicines, Inc., the company rebranded as Graphite Bio, Inc. in August 2020 to reflect its focus on gene editing technologies. The company's core strategy revolves around leveraging its gene editing platform to target the root causes of genetic diseases. Their lead product candidate, GPH101, is designed to directly correct the mutation responsible for sickle cell disease, aiming to restore normal adult hemoglobin expression. In addition to GPH101, Graphite Bio is developing GPH201 for X-linked severe combined immunodeficiency syndrome (X-SCID) and GPH301 for Gaucher disease. These programs represent a pipeline of potential therapies addressing significant unmet medical needs. Graphite Bio operates primarily in the United States, focusing on research, development, and clinical trials to advance its gene editing candidates through the regulatory approval process. The company's approach involves autologous hematopoietic stem cell products, where a patient's own cells are modified and reintroduced to provide a functional cure.

What Products and Services Does GRPH Offer?

• Develop gene-edited autologous hematopoietic stem cell therapies.
• Target genetic mutations at the root cause of diseases.
• Focus on severe and life-threatening genetic disorders.
• Offer GPH101 for sickle cell disease, aiming to restore normal hemoglobin.
• Offer GPH201 for X-linked severe combined immunodeficiency syndrome (X-SCID).
• Offer GPH301 for Gaucher disease, addressing enzyme deficiency.

How Does GRPH Make Money?

• Develops proprietary gene editing technologies.
• Conducts research and clinical trials to validate therapies.
• Seeks regulatory approval for commercialization.
• Potentially partners with larger pharmaceutical companies for distribution.

What Industry Does GRPH Operate In?

Graphite Bio operates within the rapidly evolving biotechnology industry, specifically in the gene editing sector. This sector is characterized by high growth potential and significant investment, driven by advancements in gene editing technologies like CRISPR-Cas9. The competitive landscape includes companies focusing on various gene editing approaches and therapeutic areas. Graphite Bio's focus on directly correcting genetic mutations differentiates it from competitors using other gene editing techniques. The gene editing market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of genetic diseases and the demand for curative therapies. Success in this market requires navigating complex regulatory pathways and demonstrating clinical efficacy.

Who Are GRPH's Key Customers?

• Patients with sickle cell disease.
• Patients with X-linked severe combined immunodeficiency syndrome.
• Patients with Gaucher disease.
• Healthcare providers treating these conditions.

Net buyingInsider Activity

The most recent 11 insider filings for Graphite Bio, Inc. break down as 0 sales and 11 purchases. On net that is roughly 440K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Graphite Bio, Inc.

Revenue for Graphite Bio, Inc. came in at $1.9M during Q1 2026, a 19.7% improvement versus the preceding quarter. The company recorded a net loss of $41.5M, with diluted EPS of $-1.32. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, GRPH averaged $-0.92 in diluted EPS.

GRPH Valuation & Market Position

With a $185.19M market cap, Graphite Bio, Inc. sits in the micro-cap segment of the market.

ROE -47%Key Financial Metrics

Return on equity for Graphite Bio, Inc. stands at -46.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -49.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -61.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Graphite Bio, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.65 places it in the grey zone, a middle ground that warrants monitoring.

4/7 beatsEarnings Track Record

Graphite Bio, Inc. has beaten Wall Street's EPS estimate in 4 of its last 7 reported quarters — more hits than misses. Reported results have landed about 25.0% below estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Graphite Bio, Inc. revenue of about $19.1M for fiscal 2026, with EPS near $-0.40.

Company Profile

Graphite Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Kimberlee Cobleigh Drapkin CPA. GRPH has traded publicly since 2021.

GRPH Financials

GRPH Latest News

No recent news available for GRPH.

GRPH Analyst Consensus

GRPH MoonshotScore

Graphite Bio, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources